Growth of five distinct patient-derived organoid models was dose-dependently inhibited by CDDD11-8 (IC50 range: 272-771 nM), including three derived from MYC amplified, chemo-resistant TNBC ...

Efficacy of plogosertib (CYC149462), a novel orally bioavailable PLK1 inhibitor, on patient-derived models of colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to address ...

This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that affects an estimated 2.4 to 3.1 million people in the US alone. Despite decades of research, ...